Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07234591
NA

A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis

Sponsor: Usynova Pharmaceuticals Ltd.

View on ClinicalTrials.gov

Summary

A Study to evaluate efficacy and safety in subjects with moderate to severe Plaque Psoriasis treated with a TYK2 Inhibitor for 12 weeks

Official title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

140

Start Date

2025-10-21

Completion Date

2026-05-30

Last Updated

2025-11-18

Healthy Volunteers

No

Interventions

DRUG

Tyk2 inhibitor

Specific dose of Tyk2 inhibitor on specific days

DRUG

Placebo

Specified dose of Placebo on specified days.

Locations (1)

Shanghai Skin Disease Hospital

Shanghai, China